OncoMatch

OncoMatch/Clinical Trials/NCT06562166

Online Adaptive Radiotherapy for Cervical Cancer

Is NCT06562166 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies non-drug interventions for cervical cancer.

Phase 2RecruitingPeking Union Medical College HospitalNCT06562166Data as of Jun 2026Location: China

This study aims to evaluate the clinical efficacy and safety of online adaptive radiotherapy for cervical cancer patients received radical radiotherapy. By comparing with image-guided radiotherapy, the study explores the potential advantages of online adaptive radiotherapy in reducing treatment toxicity and improving local control.

Check if I qualify

Extracted eligibility criteria

Cancer type

Cervical Cancer

Disease stage

Required: Stage II, IIIB, IIIC1

Performance status

ECOG 0–2(Ambulatory, capable of self-care)

Demographics

Ages ≤ 80
Female only

Prior therapy

No prior treatment (treatment-naive required)
Max 0 prior lines

Cannot have received: radiotherapy

Have received radiotherapy in the past

Cannot have received: chemotherapy

Have received chemotherapy in the past

Cannot have received: surgery

Have undergone radical surgery for cervical cancer

Lab requirements

Blood counts

NEUT ≥ 1.5*10^9/L, HGB ≥ 60g/L, platelets ≥ 100×10^9/L

Kidney function

blood creatinine <1.5 mg/dL

Liver function

AST and ALT are within 2 times the upper limit of normal

Complete blood count and basal metabolic indexes within 14 days before enrolment must meet the following requirements: NEUT ≥ 1.5*109/L, HGB ≥ 60g/L, platelets ≥ 100×109/, blood creatinine <1.5 mg/dL. AST and ALT are within 2 times the upper limit of normal

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Frequently asked questions

Is NCT06562166 currently recruiting?

Yes, this trial is currently recruiting patients.

Can patients have received prior systemic therapy?

No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.

What disease stage is eligible?

Stage II or IIIB or IIIC1 is required.

Is there an age limit?

Yes. Patients must be 80 years or younger.

Is this trial open to male patients?

No. This trial enrolls female patients only.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify